Senzime AB Overview
Pro stress-test →Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared patient monitoring systems, including TetraGraph® and ExSpiron® 2Xi for monitoring neuromuscular and respiratory functions during and after surgery. The company's mission is to help eliminate postoperative complications for more than 100 million patients worldwide.
Strategic Profile
Pro stress-test →Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The company has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to their Root monitoring system and digital hubs for hospital integration. Senzime operates in Sweden, Germany and the USA.
Competitive Landscape
Pro stress-test →Main competitors include Philips, IDMed, Xavant, EB Neuro, and Boston Scientific in the patient monitoring space. Senzime differentiates through specialized focus on perioperative monitoring and quantitative neuromuscular assessment, occupying a niche segment within larger medical device ecosystems.
Industry Context
Senzime AB operates in Medical Devices - Perioperative Monitoring.
Key facts
Founded: 1999 · Headquarters: Uppsala, Sweden · Employees: 58 · Revenue: $7.75M (TTM, as of Jun 2025) · Market cap: $117M